Helping pregnant smokers quit: a multi-centre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Sample size may have been too small to detect differences in less frequent adverse effects.

Routine monitoring of smoking cessation and birth outcomes in pregnant women using nicotine patches and e-cigarettes and further studies are needed to confirm these results.

Who Took Part

By PubMed's age tags, the people studied were infants, women only.

Participants sourced further supplies themselves as needed.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A pragmatic multi-centre randomised controlled trial.

Twenty-three hospitals across England, and a Stop Smoking Service in Scotland.

What Was Measured

Routine monitoring of smoking cessation and birth outcomes in pregnant women using nicotine patches and e-cigarettes and further studies are needed to confirm these results.

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 27, No. 13.

PubMed files the paper under topics including Smoking Cessation, Electronic Nicotine Delivery Systems, Nicotine, Smokers, Bayes Theorem, Birth Weight and Tobacco Use Cessation Devices.

Author keywords: E-CIGARETTES, NICOTINE REPLACEMENT TREATMENT, PREGNANCY, RANDOMISED CONTROLLED TRIAL and VAPING.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Health technology assessment (Winchester, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.